Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

87.63EUR
11:39am EDT
Change (% chg)

€-1.07 (-1.21%)
Prev Close
€88.70
Open
€88.68
Day's High
€88.73
Day's Low
€87.33
Volume
2,012,519
Avg. Vol
2,427,447
52-wk High
€92.97
52-wk Low
€66.72

Select another date:

BRIEF-Sanofi and Regeneron announce EU approval for Kevzara

* Sanofi and Regeneron announce approval of Kevzara(®) (sarilumab) to treat adult patients with moderately to severely active rheumatoid arthritis in the European Union

BRIEF-Rosa & Co announces renewal of multi-yr research agreement with Sanofi

* Rosa & Co announces renewal of multi-year research agreement with Sanofi

Sanofi chief says U.S. Supreme Court ruling on biologics has "immediate impact"

PARIS The U.S Supreme Court decision to speed access to copycat biologics drugs on Monday was expected but has an "immediate impact", Sanofi Chief Executive told Reuters.

Sanofi chief says U.S. Supreme Court ruling on biologics has "immediate impact"

PARIS The U.S Supreme Court decision to speed access to copycat biologics drugs on Monday was expected but has an "immediate impact", Sanofi Chief Executive told Reuters.

Sanofi chief says U.S. Supreme Court ruling on biologics has "immediate impact"

PARIS, June 16 The U.S Supreme Court decision to speed access to copycat biologics drugs on Monday was expected but has an "immediate impact", Sanofi Chief Executive told Reuters.

BRIEF-Parexel collaborates with Sanofi to advance use of wearable devices in life science industry

* Parexel collaborates with Sanofi to advance the use of wearable devices in life science industry

Sanofi to invest further in biologics

PARIS Sanofi announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics production, an area of strong growth potential.

UPDATE 1-Sanofi to invest further in biologics

* plans annual spending of 600 mln eur in biotechnology production

Sanofi to invest further in biologics

PARIS, June 14 French drugmaker and healthcare group Sanofi on Wednesday announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics, seen as an area with a strong growth potential.

Sanofi-Regeneron's Praluent cuts cholesterol in Odyssey trials

PARIS France's Sanofi and partner Regeneron Pharmaceuticals said on Sunday their anti-cholesterol drug Praluent recorded positive results in its first dedicated studies involving patients with diabetes and high cholesterol.

Select another date:

More From Around the Web